Pharmaceutical company Biogen has said its second-quarter net profit fell following the acquisition of rights outside the US to the experimental multiple sclerosis drug Fampridine-SR.
Excluding the acquisition, however, the results beat Wall Street expectations. Biogen is Elan's partner in the multiple sclerosis drug Tysabri.
It said net profit fell to $143m, or 49 cents a share, from $206.6m, or 70 cents a share a year ago. Revenue rose to $1.1 billion from about $1 billion a year ago.
Global sales of Tysabri rose to $254m from $200m a year ago. At the end of June, about 43,300 patients were on Tysabri, compared with 40,000 at the end of March.
